Lifecare tests groundbreaking technology to analyze human data a
Verd et lodd?
ifecare tests groundbreaking technology to analyze human data and strengthens core team
29.11.2019, Oslo – Today Lifecare AS, a Norwegian life-science company, announced that they are getting ready to test their sensing technology on human data. This is a significant advancement in the development of the solutions to address the diabetes epidemic.
Lifecare AS researches and develops miniature sensors for convenient glucose monitoring for a global market. The testing is the next phase of the development of the technology and it enables the company to generate human data, earlier than expected, with the groundbreaking technology.
“This is another step towards miniaturizing the Sencell Glucose Sensor,” says Dr Andreas Pfûtzner, CSO, Lifecare. “The sensor has now been developed to a point where it is already smaller than the initial targeted size. This allows the sensing element to be put into a hypodermic needle. A needle sensor will also represent an additional product opportunity. We are proud that we are now able to start the testing after initiating the regulatory process for the first clinical study.”
Lifecare is developing an implantable continuous glucose sensor based on its proprietary osmotic pressure cell technology. The news about the upcoming tests comes after Lifecare announced in April 2019 that its nanosensor technology has been shown in laboratory experiments to accurately measure pressure changes derived from substantially smaller osmotic pressure chambers than previously available.
Strengthening core team
In this process, Lifecare has increased its team with two talented new colleagues; Dr. Konstantin Kloppstech, a world leading expert in sensor-technology and former Head of Technology at cantiMED, and Dr. Frank Flacke, the former Medical Director Devices in the global CVD division of Sanofi. Both have now joined Lifecare’s core team and are together spearheading the sensor development. Kloppstech and Flacke have purchased shares in Lifecare from the Chairman of the Board, Christian Saure – please see separate press release.
ifecare tests groundbreaking technology to analyze human data and strengthens core team
29.11.2019, Oslo – Today Lifecare AS, a Norwegian life-science company, announced that they are getting ready to test their sensing technology on human data. This is a significant advancement in the development of the solutions to address the diabetes epidemic.
Lifecare AS researches and develops miniature sensors for convenient glucose monitoring for a global market. The testing is the next phase of the development of the technology and it enables the company to generate human data, earlier than expected, with the groundbreaking technology.
“This is another step towards miniaturizing the Sencell Glucose Sensor,” says Dr Andreas Pfûtzner, CSO, Lifecare. “The sensor has now been developed to a point where it is already smaller than the initial targeted size. This allows the sensing element to be put into a hypodermic needle. A needle sensor will also represent an additional product opportunity. We are proud that we are now able to start the testing after initiating the regulatory process for the first clinical study.”
Lifecare is developing an implantable continuous glucose sensor based on its proprietary osmotic pressure cell technology. The news about the upcoming tests comes after Lifecare announced in April 2019 that its nanosensor technology has been shown in laboratory experiments to accurately measure pressure changes derived from substantially smaller osmotic pressure chambers than previously available.
Strengthening core team
In this process, Lifecare has increased its team with two talented new colleagues; Dr. Konstantin Kloppstech, a world leading expert in sensor-technology and former Head of Technology at cantiMED, and Dr. Frank Flacke, the former Medical Director Devices in the global CVD division of Sanofi. Both have now joined Lifecare’s core team and are together spearheading the sensor development. Kloppstech and Flacke have purchased shares in Lifecare from the Chairman of the Board, Christian Saure – please see separate press release.
Redigert 21.01.2021 kl 06:37
Du må logge inn for å svare
-
«
- 1
- 2 »
Åtti8
15.11.2024 kl 23:08
962
Merlin_333 skrev Jeg håber, at du snart holder din kæft, eller falder død om🤞🤞
Si meg, er moderator fraværende?
Løgn, trusler og dødsønsker- enda godt jeg aldri har brydd meg om slike mennesker
Trigger i dag var at jeg påpeker lav kurs på økende volum, og ber Life våkne...
Løgn, trusler og dødsønsker- enda godt jeg aldri har brydd meg om slike mennesker
Trigger i dag var at jeg påpeker lav kurs på økende volum, og ber Life våkne...
Redigert 15.11.2024 kl 23:13
Du må logge inn for å svare
Åtti8
16.11.2024 kl 20:19
764
Kort oppsummert:
Antall kjæledyr i USA:
Hunder: ~89,7 millioner.
Katter: ~94,2 millioner.
Forekomst av diabetes:
Hunder: 1 av 300 (~0,33 %), tilsvarer ~299 000 hunder.
Katter: 1 av 230 (~0,43 %), tilsvarer ~409 000 katter.
Totalt diabetiske kjæledyr i USA: ~708 000 (299 000 hunder + 409 000 katter).
Estimert adopsjonsrate for Sencell: 10–20 %, som tilsvarer 70 800 til 141 600 kjæledyr.
Årlige inntekter og fortjeneste med Sencell:
Årlig inntekt per Sencell ved 8 000 kroner (antagelse, lagt lavt da konkurrent ligger på 15 000 pr.år) per kjæledyr.
Ved 10 % adopsjonsrate (70 800 kjæledyr):
Årlig inntekt: 566,4 millioner kroner.
Årlig fortjeneste (40 % margin): 226,56 millioner kroner.
Ved 20 % adopsjonsrate (141 600 kjæledyr):
Årlig inntekt: 1,1328 milliarder kroner.
Årlig fortjeneste (40 % margin): 453,12 millioner kroner
Antall kjæledyr i USA:
Hunder: ~89,7 millioner.
Katter: ~94,2 millioner.
Forekomst av diabetes:
Hunder: 1 av 300 (~0,33 %), tilsvarer ~299 000 hunder.
Katter: 1 av 230 (~0,43 %), tilsvarer ~409 000 katter.
Totalt diabetiske kjæledyr i USA: ~708 000 (299 000 hunder + 409 000 katter).
Estimert adopsjonsrate for Sencell: 10–20 %, som tilsvarer 70 800 til 141 600 kjæledyr.
Årlige inntekter og fortjeneste med Sencell:
Årlig inntekt per Sencell ved 8 000 kroner (antagelse, lagt lavt da konkurrent ligger på 15 000 pr.år) per kjæledyr.
Ved 10 % adopsjonsrate (70 800 kjæledyr):
Årlig inntekt: 566,4 millioner kroner.
Årlig fortjeneste (40 % margin): 226,56 millioner kroner.
Ved 20 % adopsjonsrate (141 600 kjæledyr):
Årlig inntekt: 1,1328 milliarder kroner.
Årlig fortjeneste (40 % margin): 453,12 millioner kroner
Redigert 16.11.2024 kl 20:19
Du må logge inn for å svare
Kaloix
17.11.2024 kl 02:10
685
Vel, 2 år til så får vi se. Hva som skjer med kurs i mellomtid er irrelevant. Nov 2026, det er mitt mål. Dette er mitt siste innlegg til vi kommer dit eller et bud realiseres.
Åtti8
17.11.2024 kl 09:58
604
Tja, høyst relevant at ikke Life fortsetter å trykke aksjer hver gang strømregningen kommer, utover det så er det bud, partner eller kommersialisering som gjelder.
-
«
- 1
- 2 »